Challenging Invasive Fungal Infections: Current and Emerging Pharmacologic Strategies

Target Audience
Primary audience: This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other healthcare providers responsible for the management of invasive fungal infections.

Secondary audience: Primary care providers, GI, dermatology, and rheumatology specialists who work in the endemic areas or who see patients receiving biologics who are at risk for endemic mycoses.

Program Overview
This is the second enduring activity derived from the live virtual event, MSGERC Town Hall: Challenging Infective Fungal Infections held on August 19, 2022. This activity, part of the Medical Mycology: Closing Gaps in Care initiative, has an expanded focus on therapeutic options, pharmacologic optimization, limitations of existing regimens, and emerging pharmacologic approaches. We will address these topics through 3 challenging clinical scenarios: a pulmonary infection in a post-lung-transplant patient; an acute myelogenous leukemia (AML) patient post chemotherapy with skin lesions, and a 51-year-old woman presenting with headaches and mental status changes. We hope that you find these cases helpful in your efforts to improve outcomes for patients with challenging invasive fungal infections.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Identify unmet needs in the treatment of challenging invasive fungal infections
Optimize the pharmacologic aspects of antifungal therapy for challenging invasive fungal infections
Discuss the profile of emerging antifungal agents and where they may fit into the treatment schema for invasive fungal infections